Welcome to our dedicated page for Ligand Pharma SEC filings (Ticker: LGND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ligand Pharmaceuticals Inc. (NASDAQ: LGND) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8‑K and other key documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on Ligand’s royalty‑focused biopharmaceutical business, financing activities and material agreements that support its model of funding mid‑ to late‑stage drug development, purchasing royalty rights and licensing technology platforms.
Ligand’s recent 8‑K filings describe events such as the completion of a private offering of 0.75% convertible senior notes due 2030, amendments to its credit agreement with Citibank, N.A., and the entry into material definitive agreements. Other 8‑Ks report quarterly financial results, including revenue composition and non‑GAAP measures, and discuss transactions like royalty financing agreements and the closing of a merger involving a Ligand subsidiary that became part of Pelthos Therapeutics. Filings also confirm that Ligand’s common stock trades on The Nasdaq Global Market under the symbol LGND and identify Jupiter, Florida as the location of its principal executive offices.
On Stock Titan, these SEC filings are paired with AI‑powered summaries designed to make complex regulatory language more accessible. Annual reports on Form 10‑K and quarterly reports on Form 10‑Q can be reviewed for discussions of Ligand’s business model, risk factors and segment information, while current reports on Form 8‑K highlight specific material events such as financings, credit facility amendments and significant portfolio transactions. Insider transaction reports on Form 4, when available, provide visibility into equity transactions by directors and officers.
Real‑time updates from EDGAR ensure that new LGND filings appear promptly, and AI analysis helps explain how each document relates to Ligand’s strategy of building diversified royalty and technology revenue streams. This combination allows investors and researchers to move efficiently from raw filings to a clearer understanding of the company’s regulatory and financial disclosures.
Ligand Pharmaceuticals director John W. Kozarich reported selling a total of 467 shares of common stock on April 1, 2026 in a series of open-market transactions. The reported weighted-average sale prices ranged from about $199.97 to $204.26 per share.
These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 7, 2025. After the sales, Kozarich directly holds 42,253 shares of Ligand Pharmaceuticals common stock.
Ligand Pharmaceuticals’ CLO & Secretary Andrew Reardon exercised stock options and sold the resulting shares. He exercised 5,000 Employee Stock Options at an exercise price of $52.27 per share, receiving 5,000 shares of common stock.
On the same date, he sold all 5,000 shares in multiple open-market transactions at weighted-average prices ranging from about $198.40 to $204.82 per share, under a written Rule 10b5-1 trading plan adopted on November 24, 2025. Following these transactions, he directly holds 41,382 shares of Ligand common stock.
LGND Rule 144 notice discloses reported dispositions of Common stock. The filing lists an issuer broker entry at UBS Financial Services and shows multiple reported sales by John Kozarich of 467 shares on 01/02/2026, 02/02/2026, and 03/02/2026 with reported amounts $88,532.51, $91,490.02, and $93,632.38 respectively.
Director John L. LaMattina of LIGAND PHARMACEUTICALS INC exercised stock options and sold the resulting shares. He exercised a non-qualified stock option for 2,161 shares of common stock at an exercise price of $114.15 per share, then sold 2,161 shares of common stock in an open-market transaction at $200.76 per share on the same day. Following these transactions, he directly holds 30,724 shares of Ligand common stock. The option position associated with these 2,161 shares is now fully exercised.
Ligand Pharmaceuticals’ Chief Financial Officer Octavio Espinoza received equity awards as part of his compensation. He was granted stock options covering 23,527 shares of common stock at an exercise price of $202.55 per share, expiring on March 2, 2036. These options vest as to 12.5% of the underlying shares six months after the grant date, then in 42 substantially equal monthly installments.
He also received 4,933 restricted stock units (RSUs), each representing one share of common stock. The RSUs vest in three substantially equal annual installments on February 15, 2027, February 15, 2028, and February 15, 2029, subject to continued service. Delivery of shares on each vesting date will be deferred under the company’s Nonqualified Deferred Compensation Plan. Following the RSU grant, he directly owns 37,945 shares of common stock.
Ligand Pharmaceuticals Chief Executive Officer Todd C. Davis reported equity awards consisting of stock options and restricted stock units. He received options to buy 50,058 shares of common stock at an exercise price of $202.55 per share, expiring on March 2, 2036.
The option grant vests as to 12.5% of the underlying shares six months after the grant date and then in 42 substantially equal monthly installments. Davis also received 10,495 restricted stock units, each representing one share of common stock, which vest in three equal annual installments on February 15, 2027, February 15, 2028, and February 15, 2029, with delivery of shares deferred under a company plan.
Ligand Pharmaceuticals’ CLO & Secretary Andrew Reardon reported equity compensation awards. He received 4,513 shares of common stock as a grant, bringing his direct common stock holdings to 41,382 shares.
He was also granted an option for 21,525 shares at an exercise price of 202.55 per share. The option vests 12.5% six months after the March 2, 2026 grant date and then in 42 equal monthly installments. The 4,513-share grant represents restricted stock units that vest in three equal annual installments on February 15, 2027, February 15, 2028, and February 15, 2029, with delivery of shares deferred under a company plan.
Ligand Pharmaceuticals Inc — The Vanguard Group filed Amendment No. 11 to a Schedule 13G/A reporting that, after an internal realignment, it reports 0 shares beneficially owned and 0% of the class of Common Stock as of the filing. The filing explains certain Vanguard subsidiaries now report separately in reliance on SEC Release No. 34-39538 and that Vanguard Inc. no longer is deemed to have beneficial ownership of securities held by those subsidiaries. The form lists Vanguard's address and is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
Ligand Pharmaceuticals director Stephen L. Sabba reported an open-market sale of 1,000 shares of Common Stock. The shares were sold on March 23, 2026 at an average price of $207.8727 per share, as detailed across multiple small trades that day.
After this transaction, Sabba directly holds 32,793 shares of Ligand Pharmaceuticals Inc. A footnote explains that this total includes 1,209 previously reported restricted shares that were granted in 2025 and are expected to vest in full within six months from the reported date.
LGND reported an insider sale. Stephen L. Sabba reported the sale of 2,034 common shares on 03/03/2026 with an aggregate figure shown as $409,851.00 in the filing. The notice also records an earlier exercised block of 1,000 shares on 03/05/2024 noted as "Exercised Shares" for cash.